These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

698 related items for PubMed ID: 36252494

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis.
    Zhang L, Huang L, Liu Z, Ling T.
    Technol Cancer Res Treat; 2024; 23():15330338241273286. PubMed ID: 39110075
    [Abstract] [Full Text] [Related]

  • 3. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
    Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y, Zhao H, Hong S, Zhang L.
    J Immunother Cancer; 2018 Dec 22; 6(1):155. PubMed ID: 30577837
    [Abstract] [Full Text] [Related]

  • 4. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q, Fang Z, Liu M, Xu R, Yi F, Wei Y, Zeng L, Zhang W.
    J Clin Pharm Ther; 2021 Dec 22; 46(6):1519-1530. PubMed ID: 34101874
    [Abstract] [Full Text] [Related]

  • 5. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
    Peng TR, Lin HH, Tsai FP, Wu TW.
    Thorac Cancer; 2021 Nov 22; 12(21):2873-2885. PubMed ID: 34545685
    [Abstract] [Full Text] [Related]

  • 6. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
    Zhou F, Zhao W, Gong X, Ren S, Su C, Jiang T, Zhou C.
    J Immunother Cancer; 2020 Sep 22; 8(2):. PubMed ID: 32900864
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y, Liang X, Li H, Chen X.
    Chin Med J (Engl); 2023 Sep 20; 136(18):2156-2165. PubMed ID: 37596898
    [Abstract] [Full Text] [Related]

  • 8. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Tan Z, Zhang J, Xu L, Wang H, Mao X, Zou R, Wang Q, Han Z, Di Z, Wu D.
    PLoS One; 2023 Sep 20; 18(10):e0290644. PubMed ID: 37844117
    [Abstract] [Full Text] [Related]

  • 9. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
    Li D, Tang L, Hu J, Cao X, He Y.
    J Cancer Res Clin Oncol; 2023 Mar 20; 149(3):933-939. PubMed ID: 35751682
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.
    Sun H, Bu F, Li L, Zhang X, Xin X, Yan J, Huang T.
    Ann Pharmacother; 2024 Apr 20; 58(4):349-359. PubMed ID: 37488978
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Soria F, Teoh JYC, Egawa S, Powles T, Shariat SF, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).
    Eur J Cancer; 2021 Jul 20; 151():35-48. PubMed ID: 33962359
    [Abstract] [Full Text] [Related]

  • 15. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
    Zhu X, Shanzhou Q, Li D, Pang X, Ma D.
    BMC Cancer; 2021 Nov 10; 21(1):1195. PubMed ID: 34758782
    [Abstract] [Full Text] [Related]

  • 16. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Huang D, Sun F, Ke L, Li S.
    Int Immunopharmacol; 2024 Sep 10; 138():112576. PubMed ID: 38941672
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.
    Zheng J, Deng Y, Huang B, Chen X.
    Front Med (Lausanne); 2023 Sep 10; 10():1198950. PubMed ID: 37583422
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
    Fei S, Lu Y, Chen J, Qi J, Wu W, Wang B, Han Y, Wang K, Han X, Zhou H, Wang J, Chen J.
    Chemotherapy; 2023 Sep 10; 68(4):197-209. PubMed ID: 37331333
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H, Chen P, Cai X, Chen C, Zhang X, He L, Zhou Y, Hong S, Zhang B.
    Cancer Immunol Immunother; 2022 Mar 10; 71(3):637-644. PubMed ID: 34297160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.